MAP2K7 and melanoma: It is suggested that combination therapy of vemurafenib with the MEK inhibitor cobimetinib is not only more effective in combating resistance of melanoma cells but also in preventing cutaneous adverse events, including the formation of cSCCs [for review, see, e.g., (26)].